Aislinn Antrim, Managing Editor

Venetoclax is already approved for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in some adults with newly diagnosed acute myeloid leukemia.

Patients treated with berubicin in clinical trials appeared to demonstrate positive responses, including 1 durable complete response in a phase 1 human clinical trial.

Study findings could offer a new approach to the toxin-based approach of other C. difficile vaccines in development.

Trial identifies no new safety signals, as emicizumab continues to demonstrate effective bleeding control with a high proportion of participants achieving zero treated bleeds.

By adequately working with students in advance and giving them ample opportunities to practice, pharmacy schools can prepare students for the future of the profession.

The 22F and 33F serotypes, which are associated with high rates of invasiveness and antibiotic resistance, are unique to the pneumococcal 15-valent conjugate vaccine.

Despite a clear trend toward improvement among patients with tumors expressing programmed death-ligand 1, the trial did not meet its primary endpoints.

Because of its rapid emergence during the COVID-19 pandemic, experts have had to make quick decisions regarding treatment of multisystem inflammatory syndrome with no evidence base and little understanding of its pathophysiological characteristics.

The companies completed the rolling submission of their application in May 2021, and the Prescription Drug User Fee Act goal date for a decision is in January 2022.

Men under 55 years of age had a 25% lower risk of heart attack and stroke, whereas men over 60 had a 15% reduced risk with testosterone supplementation.

Individuals with COVID-19 who had not had a flu shot were up to 20% more likely to be admitted to the ICU and were up to 58% more likely to visit the emergency department.

In one program, hospital pharmacists received alerts whenever an antiretroviral was prescribed in the emergency department, enabling prompt action.

Specialty pharmacists have the expertise and respect necessary to change the health care system while listening to patients’ needs and guiding them through difficult experiences.

The trial has successfully enrolled 17 patients with clear cell renal cell carcinoma and has reported that the drug is well tolerated at doses of up to 525 mg weekly.

Individuals with at least one inactive copy of the gene have lower BMIs and, on average, face a 54% lower risk of obesity than individuals without the mutations.

Despite the encouraging progression-free survival findings, data on overall survival resulted in a partial clinical hold instituted by the FDA.

The study plans to enroll approximately 180 participants to evaluate the safety, reactogenicity, and immunogenicity of its quadrivalent seasonal influenza mRNA vaccine in adults 18 years and older.

Similar effects were seen both with and without an SGLT2 inhibitor, according to investigators.

The risk for developing the rare neurological condition are low following vaccination, with the FDA noting the benefits of vaccination far outweigh the potential risks.

The approval marks the first nonsteroidal mineralocorticoid receptor antagonist proven to significantly slow chronic kidney disease progression and reduce cardiovascular risk in individuals with chronic kidney disease associated with type 2 diabetes.

Results from the APOLLO trial showed a significant 37% reduction in the risk of progression or death, compared to pomalidomide and dexamethasone alone in patients with multiple myeloma.

The FDA also granted Breakthrough Therapy Designation to tezepelumab for patients with severe asthma without an eosinophilic phenotype in September 2018.

No significant differences were found in blood pressure, blood sugar levels, or kidney function when comparing both medications among patients with type 2 diabetes.

The companies say COVID-19 booster shots may be necessary, although the FDA and CDC have disagreed.

The data show that the maximum tolerated dose of rigosertib in combination with nivolumab was not reached in the 3 cohorts of the trial’s dose-escalation phase in patients with advanced KRAS-positive metastatic lung adenocarcinoma.

The new results add to earlier findings from the EMPEROR-Reduced phase 3 trial, which found that empagliflozin reduced the combined relative risk of cardiovascular death or hospitalization for heart failure by 25% compared to placebo.

The updated label follows controversy surrounding aducanumab’s approval in June 2021, despite hesitation from experts on the drug’s efficacy.

Dollar General’s expansion into health care space will include an increased assortment of cough and cold, dental, nutritional, medical, health aids, and feminine hygiene products in many stores.

Study’s secondary endpoints were also met, including the achievement of endoscopic improvement, histologic-endoscopic mucosal improvement, and corticosteroid-free clinical remission at week 52.

Patients with diabetes treated with liraglutide also saw more weight loss compared with patients in the other arms of the study.